Broad advances in understanding HIV resistance to antiretrovirals: Report on the XVII International HIV Drug Resistance Workshop

Antiviral Therapy

Volumn 13, Issue 8, 2008, Pages 1097-1113

  Mascolini, Mark ^a   Larder, Brendan A ^b   Boucher, Charles A B ^c,f   Richman, Douglas D ^d   Mellors, John W ^e  

^a RDI ^*

^b RDI   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3' AZIDO 2',3' DIDEOXYGUANOSINE; ANTIRETROVIRUS AGENT; BEVIRIMAT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CMX 157; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; HEXADECYLOXYPROPYL TENOFOVIR; HUMAN IMMUNODEFICIENCY VIRUS 1 CORECEPTOR; IDX 899; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MONOCLONAL ANTIBODY; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROAB 3952; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; VIRUS RECEPTOR; ZIDOVUDINE;

ABNORMAL LABORATORY RESULT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CROSS RESISTANCE; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; GENETIC ANALYSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INFANT DISEASE; INTRAVENOUS DRUG ABUSE; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REFERENCE VALUE; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS RECOMBINATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; WORKSHOP;

EID: 58149522617     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways. Antivir Ther 2008; 13 Suppl 3:A9.
2. Miller MD, Danovich RM, Ke Y, et al. Longitudinal analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from P005, a phase II study in treatment-experienced patients. Antivir Ther 2008; 13 Suppl 3:A8.
3. Hatano H, Lampiris H, Huang W, et al. Virological and immunological outcomes in a cohort of patients failing integrase inhibitors. Antivir Ther 2008; 13 Suppl 3:A12.
4. Hazuda DJ, Miller MD, Nguyen BY, Zhao J. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. Antivir Ther 2007; 12:S10.
5. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004; 305:528-532.
6. Smith PF, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007; 51:3574-3581.
7. McCallister S, Lalezari J, Richmond G, et al. HIV-1 gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir Ther 2008; 13 Suppl 3:A10.
8. Van Baelen K, Salzwedel K, De Wolf H, et al. HIV-1 susceptibility to the maturation inhibitor bevirimat is modulated by natural polymorphisms at positions 369-371 in Gag spacer peptide 1. Antivir Ther 2008; 13 Suppl 3:A30.
9. Meteer J, Koontz D, Rapp KL, et al. Novel resistance profile of the potent nucleoside analogue reverse transcriptase inhibitor 3′-azido-2′,3′-dideoxyguanosine. Antivir Ther 2008; 13 Suppl 3:A5.
10. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-125.
11. Lanier ER, Lampert B, Trost I, et al. Hexadecyloxypropyl tenofovir (CMX157) has enhanced potency in vitro against NRTI-resistant HIV relative to tenofovir and a favorable preclinical profile. Antivir Ther 2008; 13 Suppl 3:A6.
12. Murphy R, Zata C, Jakubik JJ, et al. In vitro cross-resistance profile, antiviral activity, safety and pharmacokinetics in HIV-1 infected patients of IDX899, a novel HIV-1 NNRTI with high barrier to resistance. Antivir Ther 2008; 13 Suppl 3:A7.
13. Murphy R, Zala C, Zhou XJ, et al. Antiviral activity, safety and pharmacokinetics of IDX899, a novel HIV-1 non-nucleoside reverse transcriptase inhibitor with high barrier to resistance, in treatment-naive HIV-1-infected patients. Antivir Ther 2008; 13 Suppl 3:A27.
14. de Bethune MP, Andries K, Azijn H, et al. TMC278, a new potent NNRTI, with an increased barrier to resistance and favourable pharmacokinetic profile. 12th Conference on Retroviruses and Opportunistic Infections. February 22-25, 2005. Boston. Poster 556.
15. Welch BD, Redman JP, Paul S, et al. Potent HIV-1 inhibitors with a reserve of binding energy against resistance mutations. Antivir Ther 2008; 13 Suppl 3:A3.
16. Jekle A, Chhabra M, Chou E, et al. Resistance to CCR5mAb RoAb3952 is associated with a shift in binding from the extracellular domain 2 to the N terminus of CCR5. Antivir Ther 2009; 13 Suppl 3:A4.
17. Ji C, Brandt M, Dioszegi M, et al. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Res 2007; 74:125-137.
18. Hunt G, Coovadia A, Abrams JE, et al. Low frequency K103N mutations are strongly associated with inadequate virological responses to non-nucleoside reverse transcriptase inhibitor based therapy. Antivir Ther 2008; 13 Suppl 3:A132.
19. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195:711-715.
20. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
21. Peeters M, Nijs S, Vingerhoets J, et al. Determination of phenotypic clinical cut-offs for etravirine: pooled week 24 results of the DUET-1 and DUET-2 trial. Antivir Ther 2008; 13 Suppl 3:A133.
22. Coakley E, Chappey C, Benhamida J, et al. Biological and clinical cut-off analyses for etravirine in the PhenoSense HIV assay. Antivir Ther 2008; 13 Suppl 3:A134.
23. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
24. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
25. Benhamida J, Chappey C, Coakley E, Parkin NT. HIV-1 genotype algorithms for prediction of etravirine susceptibility: novel mutations and weighting factors identified through correlations to phenotype. Antivir Ther 2008; 13 Suppl 3:A142.
26. Benhamida J, Coakley E, Parkin NT, Chappey C. Increased phenotypic susceptibility to etravirine in HIV-1 with nucleoside reverse transcriptase inhibitor resistance. Antivir Ther 2008; 13 Suppl 3:A24.
27. Gupta RK, Hill A, Sawyer AW, et al. Emergence of drug resistance after failure of first-line HAART is associated with intensity of virological monitoring: a systematic analysis of cohort and trial data specifically addressing the WHO public health approach to antiretroviral therapy. Antivir Ther 2008; 13 Suppl 3:A131.
28. Vercauteren J, Wensing AMJ, van de Vijver D, et al. Trends in transmitted drug-resistant HIV-1 in Europe (Sept 2002-Dec 2005). 6th European HIV Drug Resistance Workshop 26-28 March 2008, Budapest. Poster 5.
29. Ross LL, Dix I, Wine B, et al. Change in regional prevalence, clade and epidemiology of HIV-1 drug resistance mutations and clade among antiviral therapy-naive patients in the United States from 2000 to 2007. Antivir Ther 2008; 13 Suppl 3:A160.
30. The World Health Organization 2008 List of Mutations for Surveillance of Transmitted Drug Resistant HIV Strains. http://hivdb.stanford.edu/pages/ WHOResistanceList.html
31. Deeks SG, the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA. The prevalence of multidrug resistance among treated patients in North America and its impact on mortality. Antivir Ther 2008; 13 Suppl 3:A153.
32. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
33. Gill VS, Lima VD, Fernandes KA, Harrigan PR. Injection drug users have a higher probability of developing resistance than non-injection drug users regardless of adherence or initial treatment regimen. Antivir Ther 2008; 13 Suppl 3:A157.
34. Harrigan PR, Hogg RS, Dong WWY, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347.
35. Tsibris AMN, Arnaout R, Korber B, et al. Dynamic HIV-1 escape from vicriviroc therapy in vivo. Antivir Ther 2008; 13 Suppl 3:A97.
36. Gulick RM, Su Z, Flexner C, et al. Phase II study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196:304-312.
37. Su Z, Reeves JD, Krambrink A, et al. Response to vicriviroc in HIV-infected, treatment-experienced individuals using an enhanced version of the Trofile HIV co-receptor tropism assay [Trofile (ES)]: reanalysis of ACTG 5211 results. Antivir Ther 2008; 13 Suppl 3:A98.
38. Low AJ, Dong W, Chan D, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007; 21:F17-F24.
39. Moores A, Thielen A, Dong W, et al. Improved detection of X4 virus by V3 genotyping: application to plasma RNA and proviral DNA. Antivir Ther 2008; 13 Suppl 3:A99.
40. Thielen A, Harrigan PR, Lou AJ, et al. Improved genotypic prediction of HIV-1 coreceptor usage by incorporating V2 loop sequence variation. Antivir Ther 2008; 13 Suppl 3:A100.
41. Däumer MP, Kaiser R, Klein R, et al. Inferring viral tropism from genotype with massively parallel sequencing: qualitative and quantitative analysis. Antivir Ther 2008; 13 Suppl 3:A101.
42. Maldarelli F, Wiegand A, Palmer S, et al. Intensification with efavirenz or lopinavir/ritonavir does not reduce residual HIV-1 viraemia in patients on standard antiretroviral therapy. Antivir Ther 2008; 13 Suppl 3:A79.
43. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-11219.
44. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
45. Micek MA, Blanco AJ, Beck IA, et al. The selection, transmission and persistence of drug-resistant HIV-1 in infants prophylaxed with single-dose nevirapine varies by timing of infection. Antivir Ther 2008; 13 Suppl 3:A78.
46. Schweitzer F, Mueller SM, Daeumer M, et al. Correlations between transmitted HIV-1 drug resistance mutations and the human leukocyte antigen alleles of therapy-naive HIV patients. Antivir Ther 2008; 13 Suppl 3:A76.
47. Kearney M, Shao W, Maldarelli F, et al. HIV-1 recombination in patients infected with multiple HIV-1 variants from the same donor. Antivir Ther 2008; 13 Suppl 3:A77.
48. Palmer S, Maldarelli F, Kearney M, et al. Single cell analysis of HIV DNA from infected patients. Antivir Ther 2008; 13 Suppl 3:A75.
49. Grobler JA, Stillmock KA, Miller MD, Hazuda DJ. Mechanism by which the HIV integrase active-site mutation N155H confers resistance to raltegravir. Antivir Ther 2008; 13 Suppl 3:A41.
50. Das K, Bandwar R, White KL, et al. Structural basis for K65R function: tenofovir resistance, reduced nucleotide incorporate and excision antagonism. Antivir Ther 2008; 13 Suppl 3:A44.
51. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci U S A 2007; 104:317-322.
52. Beilhartz GL, Ehteshami M, Scarth B, et al. Zidovudine resistance related connection mutations in HIV-1 reverse transcriptase cause selective dissociation from RNase II competent complexes. Antivir Ther 2008; 13 Suppl 3:A45.
53. Brehm JH, Koontz D, Meteer JD, et al. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J Virol 2007; 81:7852-7859.
54. Brehm J, Mellors J, Sluis-Cremer N. Q509L in HIV-1 reverse transcriptase increases zidovudine resistance by promoting polymerase-competent versus RNase H-competent binding on RNA/DNA template/primers with short duplex lengths. Antivir Ther 2008; 13 Suppl 3:A46.
55. von Wyl V, Bürgisser P, Yerly S, et al. Evolution of reverse transcriptase connection domain mutations in patients on antiretroviral therapy. Antivir Ther 2008; 13 Suppl 3:A47.
56. Bandaranayake RM, Ng C, Kolli M, et al. Structural explanations to altered drug resistance pathways in HIV-1 non-clade B proteases. Antivir Ther 2008; 13 Suppl 3:A42.
57. Courcambeck J, Bouzidi M, Roche G, et al. How hepatitis C virus NS3-4A protease R155K/T strains can discriminate VX-950 and ITMN-191 but affect differentially SCH-503034. Antivir Ther 2008; 13 Suppl 3:A43.
58. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356:2614-2621.
59. Tchesnokov E, Obikhod A, Schinazi RF, Götte M. Delayed chain-termination protects the hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. Antivir Ther 2008; 13 Suppl 3:A48.